Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 23471488)

1.

A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes.

Ma J, Checklin HL, Wishart JM, Stevens JE, Jones KL, Horowitz M, Meyer JH, Rayner CK.

Diabetologia. 2013 Jun;56(6):1236-42. doi: 10.1007/s00125-013-2876-2. Epub 2013 Mar 8.

PMID:
23471488
2.

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.

Cuthbertson J, Patterson S, O'Harte FP, Bell PM.

Metabolism. 2011 Jan;60(1):52-6. doi: 10.1016/j.metabol.2010.01.001. Epub 2010 Feb 11.

PMID:
20152998
3.

A high-protein breakfast induces greater insulin and glucose-dependent insulinotropic peptide responses to a subsequent lunch meal in individuals with type 2 diabetes.

Park YM, Heden TD, Liu Y, Nyhoff LM, Thyfault JP, Leidy HJ, Kanaley JA.

J Nutr. 2015 Mar;145(3):452-8. doi: 10.3945/jn.114.202549. Epub 2014 Dec 24.

PMID:
25733459
4.

The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.

Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M.

Crit Care. 2009;13(3):R67. doi: 10.1186/cc7874. Epub 2009 May 13.

5.

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y.

Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Epub 2011 Sep 6. Erratum in: Acta Diabetol. 2012 Jun;49(3):231.

PMID:
21898126
6.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
7.

Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial.

Jakubowicz D, Froy O, Ahrén B, Boaz M, Landau Z, Bar-Dayan Y, Ganz T, Barnea M, Wainstein J.

Diabetologia. 2014 Sep;57(9):1807-11. doi: 10.1007/s00125-014-3305-x. Epub 2014 Jul 10.

PMID:
25005331
8.

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

Clin Sci (Lond). 1998 Sep;95(3):325-9.

PMID:
9730852
9.

Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.

Deane AM, Summers MJ, Zaknic AV, Chapman MJ, Fraser RJ, Di Bartolomeo AE, Wishart JM, Horowitz M.

Crit Care. 2011;15(1):R35. doi: 10.1186/cc9983. Epub 2011 Jan 21.

10.

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

Diabetes. 2002 Feb;51(2):424-9.

11.
12.

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

Diabetes Care. 1997 Dec;20(12):1874-9.

PMID:
9405910
13.

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75. doi: 10.1111/j.1464-5491.2008.02579.x.

PMID:
19046215
14.

Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.

Samocha-Bonet D, Wong O, Synnott EL, Piyaratna N, Douglas A, Gribble FM, Holst JJ, Chisholm DJ, Greenfield JR.

J Nutr. 2011 Jul;141(7):1233-8. doi: 10.3945/jn.111.139824. Epub 2011 May 18.

15.

Effects of breakfast meal composition on second meal metabolic responses in adults with Type 2 diabetes mellitus.

Clark CA, Gardiner J, McBurney MI, Anderson S, Weatherspoon LJ, Henry DN, Hord NG.

Eur J Clin Nutr. 2006 Sep;60(9):1122-9. Epub 2006 May 3.

PMID:
16670695
16.

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W.

Regul Pept. 2004 Apr 15;118(1-2):89-97. Erratum in: Regul Pept. 2005 Nov 15;131(1-3):111. Gallwitz, J Baptist [corrected to Gallwitz, Baptist].

PMID:
14759561
17.

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.

PMID:
8960841
18.

Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.

Stephens JW, Bodvarsdottir TB, Wareham K, Prior SL, Bracken RM, Lowe GD, Rumley A, Dunseath G, Luzio S, Deacon CF, Holst JJ, Bain SC.

Diabetes Res Clin Pract. 2011 Nov;94(2):199-206. doi: 10.1016/j.diabres.2011.07.014. Epub 2011 Aug 10.

PMID:
21835486
19.

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.

Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR.

Eur J Clin Invest. 1997 Jun;27(6):533-6.

PMID:
9229235
20.

Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.

Ma J, Pilichiewicz AN, Feinle-Bisset C, Wishart JM, Jones KL, Horowitz M, Rayner CK.

Diabet Med. 2012 May;29(5):604-8. doi: 10.1111/j.1464-5491.2011.03496.x.

PMID:
22004512
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk